The pharmaceutical industry suffered one of its most significant safety reckonings in recent memory when Intercept Pharmaceuticals — now a subsidiary of Italian pharma giant Alfasigma — fully withdrew Ocaliva (obeticholic acid) from the U.S. market between November 14 and 24, 2025. The withdrawal followed years of escalating FDA warnings and a final post-marketing data revelation showing that Ocaliva users faced a staggering 377% higher risk of liver transplant or death compared to patients on placebo. For the approximately 130,000 Americans living with primary biliary cholangitis (PBC) who relied on this drug as a second-line treatment, that statistic represents not just a regulatory failure — it represents lives lost, livers destroyed, and families shattered. 2026 is now the critical window for harmed patients to explore their legal options through an Ocaliva lawsuit before state statutes of limitations begin to close.
What Is Ocaliva and Why Was It Prescribed?
Ocaliva (obeticholic acid) received FDA approval in 2016 as a second-line treatment for primary biliary cholangitis, a rare autoimmune liver disease in which the immune system attacks the bile ducts, causing progressive liver damage. PBC affects roughly 130,000 Americans, the majority of them women, and for patients who could not tolerate or did not respond adequately to ursodiol — the standard first-line treatment — Ocaliva was marketed as a meaningful therapeutic option. Intercept Pharmaceuticals generated billions in Ocaliva revenue during its years on the market, positioning the drug as a breakthrough for an underserved patient population.
What patients and many physicians were not adequately told, according to mounting legal allegations, was that Ocaliva carried an unreasonable and poorly communicated risk of accelerating the very liver damage it was supposed to slow. Patients who were already vulnerable — some with compensated cirrhosis, some without any cirrhosis at all — were allegedly exposed to a drug whose chemical makeup posed an inherent liver toxicity risk that the company failed to adequately disclose or act upon in a timely manner. A critical December 12, 2024 FDA warning revealed that liver injury was occurring even in patients without cirrhosis, with some cases progressing to liver transplants and death — a finding that has become central to the expanding wave of legal claims. If you or a loved one took Ocaliva and experienced serious liver complications, understanding the full regulatory timeline is essential context for any potential Ocaliva lawsuit.
The FDA Warning Timeline: A Decade of Escalating Alerts
The regulatory story of Ocaliva is a chronology of warnings that came too late and communications that fell short — a timeline now central to failure-to-warn allegations in litigation. The U.S. Food and Drug Administration issued its first Drug Safety Communication about Ocaliva as early as 2017, just one year after approval, flagging serious concerns about incorrect dosing in patients with advanced liver disease and the resulting risk of serious liver injury.
In 2018, the FDA took the more serious step of adding a Black Box Warning — the most severe warning label available under U.S. drug regulation — after reports emerged of fatal liver injury in Ocaliva patients. A Black Box Warning is intended to alert prescribers and patients to life-threatening risks; critics of Intercept now argue that the company’s response to that warning was inadequate and that marketing practices continued to downplay the severity of risk. By 2021, the FDA restricted Ocaliva’s use specifically in PBC patients with advanced cirrhosis after concluding that the drug could cause serious harm, including liver failure, in that population.
The regulatory pressure intensified dramatically on December 12, 2024, when the FDA issued a safety communication revealing that serious liver injury — including cases requiring transplants and resulting in death — had been documented in Ocaliva patients who did not even have cirrhosis. This finding significantly broadened the scope of potential harm beyond what earlier warnings had acknowledged and has become one of the most legally significant data points in 2026 litigation. Within months of that warning, Intercept withdrew Ocaliva from the U.S. market entirely, ending its decade-long commercial presence and opening the door to a growing wave of lawsuits now being investigated and filed across the country.
Core Legal Allegations in the Ocaliva Lawsuit
Failure to Adequately Warn
The primary legal theory driving Ocaliva litigation in 2026 is failure to warn — the allegation that Intercept Pharmaceuticals knew or should have known about the drug’s serious liver injury risks and failed to communicate those risks clearly and promptly to patients and prescribing physicians. Attorneys pursuing these cases argue that despite multiple FDA interventions spanning nearly a decade, Intercept’s labeling, marketing materials, and sales communications consistently minimized the severity of known dangers. The December 2024 FDA finding that liver injury was occurring in non-cirrhotic patients adds a particularly powerful dimension to this argument, as it suggests the company’s warnings were incomplete even for patients considered lower risk.
Design Defect
A secondary but significant claim involves design defect — the argument that obeticholic acid, the active compound in Ocaliva, is inherently dangerous in ways that make the drug unreasonably unsafe for its intended use. Plaintiffs pursuing design defect claims will need to demonstrate that the risks of the drug outweigh its benefits and that a safer alternative design or formulation was feasible. Given the FDA’s own conclusion that post-marketing data showed a 377% increased risk of liver transplant or death, attorneys believe the evidentiary foundation for design defect claims is strong.
Corporate Negligence and Post-Market Surveillance Failures
Plaintiffs are also alleging that Intercept Pharmaceuticals failed to conduct adequate post-market surveillance and to act swiftly on accumulating safety signals. The argument is that the company had access — through adverse event reports, clinical follow-up data, and FDA communications — to mounting evidence of serious harm and chose to continue marketing and distributing the drug without taking sufficient corrective action. The years between the 2018 Black Box Warning and the 2025 market withdrawal are a focal point for these negligence claims, as plaintiffs will argue the company had years to act more aggressively and failed to do so.
Qualifying Injury Categories
While every case is evaluated individually, attorneys investigating Ocaliva claims in 2026 are generally focusing on plaintiffs who experienced one or more of the following injuries while taking or shortly after taking Ocaliva:
- Acute liver failure or acute-on-chronic liver failure
- Liver transplantation
- Death attributed to liver failure or liver-related complications
- Significant worsening of existing liver disease beyond the expected progression of PBC
- Hospitalization for liver injury or liver decompensation
- Serious liver injury in patients without cirrhosis, consistent with the December 2024 FDA warning
Patients who experienced only mild side effects or whose PBC remained stable are less likely to qualify for a strong legal claim, though anyone who took Ocaliva and experienced unexpected liver complications is encouraged to consult with a mass tort attorney for a case-specific evaluation.
Ocaliva Lawsuit: Key Statistics at a Glance
| Data Point | Detail |
|---|---|
| Drug withdrawn from U.S. market | November 14–24, 2025 |
| Increased risk of liver transplant or death vs. placebo | 377% higher risk |
| Estimated U.S. PBC patients affected | Approximately 130,000 |
| First FDA safety warning issued | 2017 |
| Black Box Warning added | 2018 |
| FDA restriction for cirrhosis patients | 2021 |
| FDA warning on non-cirrhotic liver injury | December 12, 2024 |
| MDL or class action established | None as of early 2026 |
| Public settlements announced | None as of September 2026 |
| Current litigation phase | Investigation, intake, and early filing stage |
Who Is Eligible to File an Ocaliva Lawsuit in 2026?
Eligibility for an Ocaliva lawsuit in 2026 is determined by a combination of medical history, injury documentation, and timing. In general, attorneys are looking for individuals who meet the following criteria:
- Took Ocaliva as prescribed at any point during the drug’s commercial availability (2016–2025)
- Experienced a qualifying liver injury — including liver failure, liver transplant, serious liver decompensation, or death of a loved one attributed to liver complications — during or following Ocaliva use
- Have not yet exceeded the statute of limitations in their state, which typically runs two to three years from the date of injury or the date the plaintiff reasonably discovered the connection between Ocaliva and their injury
- Are able to document the injury through medical records, hospital admission records, pathology reports, or transplant documentation
Family members of patients who died due to liver failure while taking Ocaliva may also be eligible to pursue wrongful death claims on behalf of their loved ones’ estates. Given the December 2024 FDA finding that liver injury was occurring even in non-cirrhotic patients, the pool of potentially eligible plaintiffs is broader than earlier FDA warnings might have suggested. Anyone uncertain about their eligibility should consult with a qualified mass tort attorney as soon as possible, as statutes of limitations vary by state and can foreclose legal options without warning.
Current State of Ocaliva Litigation in 2026
As of 2026, Ocaliva litigation is in its active early stages — a phase characterized by intensive case investigation, plaintiff intake, and the initial filing of individual lawsuits against Intercept Pharmaceuticals and its parent company Alfasigma. The number of lawsuits filed against Intercept Pharmaceuticals continues to grow as of early 2026, reflecting the expanding awareness of the drug’s documented harms and the relatively recent market withdrawal that is prompting many patients and families to seek legal counsel for the first time.
Importantly, no established Ocaliva MDL (multidistrict litigation) or class action lawsuit exists as of early 2026. Litigation remains in the investigation and intake phase, with lawsuits in their early stages and no large-scale public settlements or jury trials announced yet as of mid-2026. This is consistent with the typical trajectory of pharmaceutical mass tort litigation, in which MDL consolidation and bellwether trials often do not occur until a sufficient volume of cases has been filed and the litigation landscape has matured. Attorneys and legal observers expect that if the volume of Ocaliva cases continues to grow at its current pace, a formal MDL petition could be filed in federal court in the coming months or years.
No Ocaliva lawsuit settlements or publicly disclosed compensation amounts have been announced as of September 2026. This means that plaintiffs who file now are doing so in the early wave of litigation — a position that historically has carried both strategic advantages and the requirement for patience, as mass tort cases typically take several years from initial filing to resolution. Early filers often benefit from greater attorney attention and, in some litigation structures, priority positioning in any eventual settlement negotiations.
The December 12, 2024 FDA warning about liver injury in non-cirrhotic patients has significantly energized the plaintiff bar, as it broadened the recognized scope of Ocaliva’s harm and provided a powerful regulatory anchor for failure-to-warn claims. Attorneys across the country are actively investigating cases and encouraging potentially eligible plaintiffs to come forward before state statutes of limitations begin to expire.
Frequently Asked Questions About the Ocaliva Lawsuit
Who can file an Ocaliva lawsuit?
Any individual who took Ocaliva and experienced a serious liver injury — including liver failure, liver transplant, or significant liver decompensation — may be eligible to file an Ocaliva lawsuit. Family members of patients who died from liver complications while taking Ocaliva may be eligible to file a wrongful death claim. Because the December 2024 FDA warning confirmed liver injury risk even in patients without cirrhosis, eligibility is not limited to patients who had advanced liver disease at the time they took the drug. A mass tort attorney can review your specific medical history and advise you on whether your case qualifies.
Was Ocaliva recalled, and what does the withdrawal mean legally?
Ocaliva was not recalled in the traditional regulatory sense — rather, Intercept Pharmaceuticals voluntarily withdrew the drug from the U.S. market between November 14 and 24, 2025, following FDA pressure and post-marketing data confirming catastrophic harm rates. Legally, the distinction between a recall and a voluntary withdrawal is less important than the underlying facts: the drug is no longer available, the FDA has confirmed serious and sometimes fatal liver injury risks, and the company made the commercial decision to remove the product rather than face continued regulatory scrutiny. This withdrawal is highly relevant to litigation because it undercuts any defense argument that the drug was safe — the company’s own decision to pull it from the market is powerful evidence that the risk-benefit calculus had become untenable.
How long do I have to file an Ocaliva lawsuit?
The time you have to file an Ocaliva lawsuit is governed by your state’s statute of limitations for personal injury or product liability claims, which typically ranges from two to three years. The clock generally starts running either from the date of your injury or from the date you reasonably discovered — or should have discovered — the connection between Ocaliva and your injury. Because Ocaliva was only withdrawn from the market in late 2025, many patients may be just now becoming aware of the link between their liver complications and the drug, which could affect when the limitations clock began. However, do not assume you have unlimited time — consult with an attorney as soon as possible to determine the specific deadline applicable to your case and jurisdiction.
Is there an Ocaliva MDL, and what does that mean for my case?
As of early 2026, no Ocaliva MDL (multidistrict litigation) has been established. Litigation is currently in the investigation and intake phase, with individual lawsuits being filed as attorneys complete case evaluations. An MDL is a federal court mechanism that consolidates pretrial proceedings for cases involving the same product and similar allegations, making litigation more efficient and creating a structure for global settlement negotiations. The absence of an MDL as of 2026 does not mean one will not be created — if case volumes continue to grow as expected, an MDL petition is a likely next step. In the meantime, cases are being filed individually, and attorneys are building the evidentiary record that will support both individual claims and any future consolidated proceedings.
What damages can Ocaliva lawsuit plaintiffs recover?
Plaintiffs who successfully pursue Ocaliva lawsuits may be eligible to recover a range of economic and non-economic damages, potentially including:
- Medical expenses — past and future costs of treating liver injury, including hospitalization, transplant surgery, post-transplant care, and ongoing monitoring
- Lost wages and loss of earning capacity — income lost due to illness, disability, or death
- Pain and suffering — compensation for the physical pain and emotional distress caused by serious liver injury
- Loss of consortium — damages available to spouses or family members for the loss of companionship and support
- Wrongful death damages — available to surviving family members when a patient’s death is attributed to Ocaliva-related liver failure
- Punitive damages — in cases where a jury finds that Intercept’s conduct was particularly egregious or reckless, additional punitive damages may be available to punish the company and deter future misconduct
Because no Ocaliva lawsuit settlements have been publicly announced as of September 2026, there are no established benchmark figures to reference at this time. Compensation amounts in pharmaceutical mass torts vary widely based on the severity of injury, the strength of causation evidence, and the jurisdiction in which the case is filed. An experienced mass tort attorney can provide a more tailored assessment of potential damages based on the specific facts of your case.
This article is for informational purposes only and does not constitute legal advice. If you believe you or a loved one was harmed by Ocaliva, please consult with a qualified attorney to discuss your specific legal rights and options.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.